Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | PARP1 | P09874 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 2/20 | 0.40 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.40 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.40 |
| ▸ | GLI1 | P08151 | 1/20 | 0.39 |
| ▸ | GLI2 | P10070 | 1/20 | 0.39 |
| ▸ | ESR1 | P03372 | 2/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | HTR2B | P41595 | 1/20 | 0.37 |
| ▸ | TYR | P14679 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2574527 | 0.85 | LMNA (0.57) | LMNAMEN1KMT2APOLBPARP1 | |
| SCHEMBL12489082 | 0.79 | PIM1 (0.51) | MEN1KMT2APOLBALDH1A1HPGD | |
| SCHEMBL13003705 | 0.78 | PARP1 (0.54) | LMNAMEN1KMT2APARP1ALDH1A1 | |
| SCHEMBL1663769 | 0.78 | PRKCI (0.56) | MEN1KMT2APARP1ALDH1A1HPGD | |
| SCHEMBL1345856 | 0.78 | PARP1 (0.50) | PARP1KDM4EHTR2A | |
| SCHEMBL144025 | 0.78 | PARP1 (0.50) | LMNAMEN1KMT2APOLBPARP1 | |
| SCHEMBL29798728 | 0.78 | PARP1 (0.50) | PARP1KDM4EHTR2A | |
| SCHEMBL29638516 | 0.78 | PARP1 (0.54) | LMNAMEN1KMT2APARP1ALDH1A1 | |
| SCHEMBL2191216 | 0.78 | ALDH1A1 (0.55) | LMNAPARP1ALDH1A1SMN1; SMN2 | |
| SCHEMBL8870966 | 0.77 | CSNK2A1 (0.49) | PARP1ALDH1A1HPGDKDM4EESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11396495-B2 | Amine compound for inhibiting SSAO/VAP-1 and use thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2022-07-26 | — | — | US | disclosed |
| US-20200377461-A1 | AMINE COMPOUND FOR INHIBITING SSAO / VAP-1 AND USE THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2020-12-03 | — | — | US | disclosed |
| US-9303026-B2 | Antiviral agents | BIOTA SCIENTIFIC MANAGEMENT PTY. LTD. (AU) | 2016-04-05 | — | — | US | disclosed |
| US-20140179709-A1 | ANTIVIRAL AGENTS | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2014-06-26 | — | — | US | disclosed |
| US-8624025-B2 | Antiviral agents | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2014-01-07 | — | — | US | disclosed |
| US-20130005736-A1 | ANTIVIRAL AGENTS | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2013-01-03 | — | — | US | disclosed |
| US-8217171-B2 | Antiviral agents | BIOTA SCIENTIFIC MANAGEMENT PTY. LTD. (AU) | 2012-07-10 | — | — | US | disclosed |
| US-20110212966-A1 | ANTIVIRAL AGENTS | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2011-09-01 | — | — | US | disclosed |
| US-7951955-B2 | Antiviral agents | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2011-05-31 | — | — | US | disclosed |
| EP-2314582-A1 | Heterocyclic compounds as antiviral agents | Biota Scientific Management Pty Ltd (AU) | 2011-04-27 | — | — | EP | disclosed |
| US-7829705-B2 | such as 7-{2-[1-(6-methyl-3-pyridazinyl)-4-piperidinyl]ethoxy}-4-ethoxy-cinnoline, used in the treatment of picornavirus infections in humans | BIOTA SCIENTIFIC MANAGEMENT PTY. LTD. (AU) | 2010-11-09 | — | — | US | disclosed |
| US-7579465-B2 | For treatment of picornavirus infections in mammals | BIOTA SCIENTIFIC MANAGMENT PTY. LTD. (AU) | 2009-08-25 | — | — | US | disclosed |
| US-20090030000-A1 | ANTIVIRAL AGENTS | BIOTA SCIENTIFIC MANAGEMENT PTY. LTD. (AU) | 2009-01-29 | — | — | US | disclosed |
| US-20070149531-A1 | such as 7-{2-[1-(6-methyl-3-pyridazinyl)-4-piperidinyl]ethoxy}-4-ethoxy-cinnoline, used in the treatment of picornavirus infections in humans | BIOTA SCIENTIFIC MANAGEMENT PTY. LTD. (AU) | 2007-06-28 | — | — | US | disclosed |
| US-20070149530-A1 | For treatment of picornavirus infections in mammals | BIOTA SCIENTIFIC MANAGEMENT PTY. LTD. (AU) | 2007-06-28 | — | — | US | disclosed |
| US-7166604-B2 | N-Heterocyclic derivatives; picornavirus infections in mammals; human rhinovirus | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2007-01-23 | — | — | US | disclosed |
| EP-1353911-A4 | ANTIVIRAL AGENTS | BIOTA SCIENT MANAGEMENT (AU) | 2005-01-05 | — | — | EP | disclosed |
| US-20040077633-A1 | N-Heterocyclic derivatives; picornavirus infections in mammals; human rhinovirus | BIOTA SCIENTIFIC MANAGEMENT PTY. LTD. (AU) | 2004-04-22 | — | — | US | disclosed |
| EP-1353911-A1 | ANTIVIRAL AGENTS | BIOTA SCIENTIFIC MANAGEMENT PTY. LTD. (AU) | 2003-10-22 | — | — | EP | disclosed |
| WO-2002050045-A1 | ANTIVIRAL AGENTS | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2002-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149530-A1 | For treatment of picornavirus infections in mammals | HAVCR2, EIF2AK2, MAVS | LMNA 898/4885MEN1 3315/4885KMT2A 4704/4885 |
| US-20090030000-A1 | ANTIVIRAL AGENTS | EIF2AK2, MAVS, ZC3HAV1 | LMNA 1613/4885MEN1 4423/4885KMT2A 4634/4885 |
| US-20130005736-A1 | ANTIVIRAL AGENTS | EIF2AK2, MAVS, ZC3HAV1 | LMNA 1613/4885MEN1 4423/4885KMT2A 4634/4885 |
| US-20110212966-A1 | ANTIVIRAL AGENTS | EIF2AK2, MAVS, ZC3HAV1 | LMNA 1613/4885MEN1 4423/4885KMT2A 4634/4885 |
| US-20070149531-A1 | such as 7-{2-[1-(6-methyl-3-pyridazinyl)-4-piperidinyl]ethoxy}-4-ethoxy-cinnoline, used in the treatment of picornavirus infections in humans | EIF2AK2, IFNAR1, HAVCR2 | LMNA 178/4885MEN1 425/4885KMT2A 4163/4885 |
| US-20140179709-A1 | ANTIVIRAL AGENTS | EIF2AK2, MAVS, ZC3HAV1 | LMNA 1613/4885MEN1 4423/4885KMT2A 4634/4885 |
| US-11396495-B2 | Amine compound for inhibiting SSAO/VAP-1 and use thereof | VCAM1, VAPB, ICAM1 | LMNA 4708/4885MEN1 4558/4885KMT2A 3514/4885 |
| US-20040077633-A1 | N-Heterocyclic derivatives; picornavirus infections in mammals; human rhinovirus | RNASEH1, RPL35, SARS1 | LMNA 1279/4885MEN1 1746/4885KMT2A 4497/4885 |
| US-20200377461-A1 | AMINE COMPOUND FOR INHIBITING SSAO / VAP-1 AND USE THEREOF | VCAM1, VAPB, ICAM1 | LMNA 4708/4885MEN1 4558/4885KMT2A 3514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.